Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
People need to understand the latest announcement is basically telling the world that the collaboration strategy is the main focus of the company at the moment. This alone could attract many more potential partners on the near future.
Pluristem's Muscle Regeneration Phase III Study Presentations. A lot of positives to take forward. Promising muscle regeneration numbers.
https://www.pluristem.com/wp-content/uploads/2022/07/HIP-topline-results-event-presentation-FINAL-PRESENTATION.pdf
Why there is still a lot of hope for PSTI in muscle regeneration:
1.PLX-PAD was demonstrated to be an effective accelerator of muscle strength and regeneration.
2. A significant increase in Hip Abduction Strength (HAS) was observed at week 26 and week 52 for patients treated with PLX-PAD (n=120), in the injured leg (p=0.047, p=0.0022) and uninjured leg (p=0.073, p=0.0046) compared to placebo (n=120)
3.PLX-PAD was well tolerated and demonstrated a significant increase in HAS.
Wondering if the phase 3 results will be good? Just look at the phase 2 results. It will take something very weird for the phase 3 results to not be great.
Wondering if the phase 3 results will be good? Just look at the phase 2 results. It will take something very weird for the phase 3 results to not be great.
"We also plan to release topline results from our multinational Phase III study for muscle regeneration following hip fracture surgery during the third calendar quarter of 2022."- Pluristem CEO back in march. Good PSTO news coming soon?
Yahoo included $PSTI as one of the top 10 Best Biotech Penny Stocks To Buy Now.
https://finance.yahoo.com/news/10-best-biotech-penny-stocks-132212951.html
The cultured meat tweet is very encouraging. Can't wait for the cultured meat proof of concept.
STEM CELLS TO HEAL BONE MARROW
http://www.stem-cells-news.com/1/stem-cells-to-heal-bone-marrow/
A new deep dive into PSTI's research.
Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. EP2366775B1, titled “Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy”, by the European Patent Office. This patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem’s methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment.
As described in the patent, Pluristem’s therapeutic cells are designed to promote the success of hematopoietic stem cell transplantation, which is used to treat patients with dysfunctional bone marrow. The damage to the bone marrow could be due to chemotherapy or exposure to high levels of radiation, such as can occur as part of treatment for certain cancers or in a nuclear catastrophe.
Successful facilitation of hematopoietic stem cell engraftment is demonstrated by an increase in the number of bone marrow cells that are responsible for producing the cells which circulate in the blood (white blood cells, red blood cells and platelets). These circulating cells are required to resist infection, transport oxygen within the body, and prevent hemorrhage.
“This patent strengthens our position in the hematologic space, and will support an anticipated clinical program for our PLX-R18 cells in the treatment of damaged bone marrow. Since damage to bone marrow can result from a range of illnesses and exposures, we hope that our product will be able to benefit many patients suffering from hard-to-treat conditions,” stated Pluristem CEO Zami Aberman. To date, Pluristem has been issued over 35 patents, and has approximately 150 more patents pending worldwide (…)
Preeclampsia Therapeutics Market Will Generate Booming Growth Opportunities to 2032 | Hoffmann-La Roche Ltd., Sera Prognostics, Pluristem Therapeutics
https://xaralite.com/238007/news/preeclampsia-therapeutics-market-will-generate-booming-growth-opportunities-to-2032-hoffmann-la-roche-ltd-sera-prognostics-pluristem-therapeutics/
Pluristem’s Cell-Based Technology Platform, Promoting a Better Future
The latest company blog, focusing on the company's current projects and future vision.
https://www.pluristem.com/pluristem-blog/pluristems-cell-based-technology-platform-promoting-a-better-future/
Pluristem has been selected as one of the 5 Biotech Penny Stocks Redditors Love.
https://www.insidermonkey.com/blog/5-biotech-penny-stocks-redditors-love-1041208/2/
Pluristem therapeutics ($PSTI) stock analysis
"Stock could go up 600% this year"
Placental Stem Cell Therapy Market Biggest Innovation.
Pluristem among Top Key Players
https://politicalbeef.co.uk/2022/04/placental-stem-cell-therapy-market-biggest-innovation-with-top-key-players-lifebank-stem-cell-banking-cynata-celularity-athersys-americord-registry-reneuron-group-reelabs-mesoblast-pluristem/
Pluristem and Tnuva Ring the Closing Bell at Nasdaq yesterday. Just shows how invested the two companies are in this partnership. Could launch $PSTI to new heights very soon.
“A quick and effective way to improve the hematological profile of sick patients—resulting in faster recovery and decreased transfusions—would be a game-changer for the field, and we will continue to explore its clinical applications. The FDA’s recognition of PLX-R18’s potential to treat ARS is also significant. This treatment potentially carries great significance for current events in Ukraine and Europe, providing hope for treatment in the case of a nuclear event. We are proud of this product line, which might hold the key to promoting wellbeing, improving the standard of care, and possibly saving lives.”
Very important statement from $PSTI. Current events in Europe and today's results could make this treatment very relevant.
The $PSTI stock is Up 25% since the announcement of the cultured meat collaboration. The company said their goal is to create many more collaborations, imagine how much the stock's value can grow.
In 2022 so far, $PSTI is outperforming the Nasdaq index by 51%. Very impressive from a stock that was going down for a long time. The new company expansion strategy is really turning things around.
Shareholders update got me very optimistic. It looks like Pluristem are putting a lot of emphasis on finding new ways to expand and to collaborate with different companies. This approach could really increase the company's value and raise the stock price by a lot.
Proof of concept for the for the cultured meat product expected in Q2.
Results of Phase III Study of Muscle Regeneration Following Hip Fracture Surgery expected in Q3.
Interesting months coming ahead.
Cultured Meat Market Statistics 2027:
The cultured meat market size was valued at $1.64 million in 2021, and is estimated to reach $2788.1 million by 2030, registering a CAGR of 95.8% from 2022 to 2030.
Pluristem could still could become a major player.
Very smart move to enter the market at this moment.
Even after the drop yesterday the stock is still Up more than 11% in the past 5 days. Overall very promising numbers from the stock.
Our subsidiary @OravaxMedical and @GenommaLab recently announced a JV. We are moving this partnership forward and today @NadavKidron Oramed CEO and Oravax Chairman, and Dr. Miriam Kidron, Oramed CSO, met with members of the Genomma team at their facility in Mexico.
Our subsidiary @OravaxMedical and @GenommaLab recently announced a JV. We are moving this partnership forward and today @NadavKidron Oramed CEO and Oravax Chairman, and Dr. Miriam Kidron, Oramed CSO, met with members of the Genomma team at their facility in Mexico. $ORMP pic.twitter.com/mJf9lmynbT
— Oramed Pharma (@OramedPharma) January 18, 2022
This week has shown many upsides for the stock.
Not only did the stock jump by 30% after the announcement, but it also managed to keep its value throughout the week. Very good sign as it shows the new collaboration has some true value to investors.
Think about what could happen if a new collaboration is announced, or when they start releasing their products to the market.
Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins
-Protease inhibitor is a key component of Oramed’s PODTM technology that protects therapeutic proteins in the digestive system
-Oramed has already been granted this patent in the United States and Japan
I found this interesting review, starts at minute 9:30:
Commissioner Nikki Fried spoke to CEO Nadav Kidron and encouraged the FDA to review oral covid vaccines as an alternative to injections.
ARDS Results Coming in the next few weeks. Could mean big news for the stock. How high can it go if the results are positive?
COVID doesn't seem to be letting up anytime soon, making the phase II ARDS results very valuable for the future of the stock with the potential to rise big in the future.
Oramed taking legal action against the shorties. This was posted elsewhere:
New Canaccord Genuity Report. Posted on another forum.
Oramed stock price target raised to $40 from $25 at Alliance Global Partners
Disagree. Just like Merck’s, Pfizer’s pill is an antiviral treatment, not a vaccine. Vaccination remains the priority to face the pandemic. Oral vaccination would be game-changing in developing countries. Huge potential here.
Also, Oramed is not developing so much a vaccine against covid as a technology that can be applied to any vaccine (and treatment, as in the case of insulin).
Just a temporary stumble. The money is to fund the clinical trials, and their success ultimately defines the stock's success. Consider where we are now: $2.59 on 11/3/20 vs. $25.08 on 11/3/21. That's an 868.34% gain in one year. Losses? Those are triple-digit gains, my friend ;)
Aegis Capital Corp Analyst Report:
Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial https://newsfilter.io/a/dd290d367b307a7dd157ede6f5b2d4db
So nothing out of the ordinary, right? In fact, 8mg seems a low dose. Maybe that’s what Nadav meant when he said that “less is more”: less insulin is actually more effective than more insulin in the pill, and that’s why the dose in the phase 3 trials is 8mg and not 16 or 24mg.
I don’t know about quantities of regular insulin, but phase 3 trials are with pills that contain 8mg doses, not 16. Although phase 2b trials looked at 16 and 24mg doses, those trials were extended with additional cohorts because the low dose proved more efficacious, and that way 8mg was defined as the optimal dose to move into phase 3 trials.
I would be very cautious with comments coming from the Vaxart board, they feel threatened by Oramed and have been saying some negative things since Oravax is getting more publicity than Vaxart.
The company posted on Twitter the presentation organized by the Brazil-Israel Chamber of Commerce, where the CEO talks about Oravax:
Watch this presentation organized by the Brazil-Israel Chamber of Commerce. Oramed CEO, Nadav Kidron, discusses Oravax Medical's oral Covid-19 vaccine currently being developed. #oralcovid19vaccine #biotech $ORMP
— Oramed Pharma (@OramedPharma) October 4, 2021
Watch here: https://t.co/wrlnPw9NuL